Lasa Supergenerics

Lasa Supergenerics EBITDA per Share

The EBITDA per Share of Lasa Supergenerics (LASA.NS) as of Nov 8, 2026 is -6.83 INR. In the previous year, EBITDA per Share was 1.25 INR — a change of -646.15% (lower).

EBITDA per Share

-6.83INR

YoY

-646.15%

Last updated:

EBITDA per Share of Lasa Supergenerics is 2026 -6.83 INR. EBITDA per Share of Lasa Supergenerics was 2025 1.25 INR. It decreases by -646.15% lower compared to the previous year.

The Lasa Supergenerics EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
3.96 INR
Jan 1, 2020
7.36 INR
Jan 1, 2021
11.63 INR
Jan 1, 2022
4.14 INR
Jan 1, 2023
-4.91 INR
Jan 1, 2024
0.45 INR
Jan 1, 2025
1.25 INR
Jan 1, 2026
-6.83 INR
The Lasa Supergenerics EBITDA per Share history
YEAREBITDA per ShareYoY
-6.83INR-646.15%
1.25INR+178.71%
0.45INR-109.14%
-4.91INR-218.53%
4.14INR-64.39%
11.63INR+58.02%
7.36INR+85.76%
3.96INR-78.07%
18.07INR-9.64%
20.00INR—
0.00INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Lasa Supergenerics Stock analysis

What does Lasa Supergenerics do? Lasa Supergenerics Ltd manufactures veterinary preparations including API products such as Albendazole, Fenbendazole, Oxfendazole, Providone Iodine, Nitroxylene, Ricobendazole, Halquinol, and others. The company also produces animal feed ingredients like potassium iodide, cobalt sulfate, sodium selenate, ethylediamine dihydroiodide, and vanadyl sulfate, as well as reagents for therapeutic use including cetylpyridinium chloride, bismuth subsalicylate, and sodium selenite. Its manufacturing facility in Mahad and Chiplun, Maharashtra, supports the production of these specialized veterinary and pharmaceutical products. The company's primary customers are likely veterinary pharmaceutical manufacturers and animal health suppliers who require API products, feed additives, and therapeutic reagents. These segments include the veterinary pharmaceutical industry and animal feed production sectors, which rely on Lasa Supergenerics' specialized chemical formulations for their own product lines. The firm's focus on catalyst chemistry and anthelmintic/veterinary API products positions it within the niche market of veterinary pharmaceutical manufacturing. Lasa Supergenerics generates revenue through the sale of its API products, animal feed ingredients, and therapeutic reagents to veterinary and pharmaceutical companies. The company's product portfolio targets the veterinary pharmaceutical sector, where demand for anthelmintic and other API-based solutions is significant. By specializing in catalyst chemistry and producing high-demand veterinary API products, the company serves a specific market segment with tailored chemical solutions. Lasa Supergenerics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lasa Supergenerics stock

EBITDA per Share of Lasa Supergenerics is -6.83 INR in 2026.

EBITDA per Share of Lasa Supergenerics changed from 1.25 INR to -6.83 INR, representing a -646.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Lasa Supergenerics since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Lasa Supergenerics

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Lasa Supergenerics